HedgeChatter

  • Home /
  • Tag Archives

AVEO

AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

[at noodls] – CAMBRIDGE, Mass. and TOKYO, Japan, November 28, 2012 — AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that the U.S. Food and Drug Administration (FDA) has accepted for … moreView todays social media effects on AVEOView the latest stocks trending across Twitter. Click to view dashboard […]

November 29, 2012 Bystocknews , Comments Off on AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma read more

PropThink: Expense Cuts Ahead of a Pivotal Year for AVEO and Tivozanib

[ACN Newswire] – By Jake KingIn a move that management says will save the company more than $100M over the next three years, AVEO Oncology (NASDAQ:AVEO) cut its work force by 17% and made strategic shifts to lighten the … moreView todays social media effects on AVEOView the latest stocks trending across Twitter. Click to view dashboard […]

October 30, 2012 Bystocknews , Comments Off on PropThink: Expense Cuts Ahead of a Pivotal Year for AVEO and Tivozanib read more